1. Market Research
  2. > Toxic Shock - Pipeline Review, H2 2013

Toxic Shock - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 25 pages

Toxic Shock - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Toxic Shock - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Toxic Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Toxic Shock. Toxic Shock - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Toxic Shock.
- A review of the Toxic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Toxic Shock pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Toxic Shock.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Toxic Shock pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Toxic Shock - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Toxic Shock Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Toxic Shock 6
Toxic Shock Therapeutics under Development by Companies 8
Toxic Shock Therapeutics under Investigation by Universities/Institutes 9
Discovery and Pre-Clinical Stage Products 10
Comparative Analysis 10
Toxic Shock Therapeutics - Products under Development by Companies 11
Toxic Shock Therapeutics - Products under Investigation by Universities/Institutes 12
Companies Involved in Toxic Shock Therapeutics Development 13
Integrated BioTherapeutics, Inc. 13
Toxic Shock - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Drug Profiles 19
TSS-HIG - Drug Profile 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
SEB-HuMab - Drug Profile 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Monoclonal Antibody Against Staphylococcal Enterotoxin B - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Drug For Staphyloccal enterotoxin B And Toxic Shock Syndrome Toxin-1 - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables

Number of Products Under Development for Toxic Shock, H2 2013 6
Products under Development for Toxic Shock - Comparative Analysis, H2 2013 7
Number of Products under Development by Companies, H2 2013 8
Number of Products under Investigation by Universities/Institutes, H2 2013 9
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 12
Integrated BioTherapeutics, Inc., H2 2013 13
Assessment by Monotherapy Products, H2 2013 14
Assessment by Stage and Route of Administration, H2 2013 16
Assessment by Stage and Molecule Type, H2 2013 18

List of Figures

Number of Products under Development for Toxic Shock, H2 2013 6
Products under Development for Toxic Shock - Comparative Analysis, H2 2013 7
Products under Development by Companies, H2 2013 8
Products under Investigation by Universities/Institutes, H2 2013 9
Discovery and Pre-Clinical Stage Products, H2 2013 10
Assessment by Monotherapy Products, H2 2013 14
Assessment by Route of Administration, H2 2013 15
Assessment by Stage and Route of Administration, H2 2013 16
Assessment by Molecule Type, H2 2013 17
Assessment by Stage and Molecule Type, H2 2013 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.